CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China.
“I am pleased to have reached this important regulatory milestone for IV oliceridine ,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. “As we work towards our August 7th PDUFA date for potential approval in the U.S., we also continue to support our ex-U.S. partnerships, as part of our mission to deliver novel treatment options to patients with moderate-to-severe acute pain.”
The Company expects to receive future milestone payments, as well as a 10% royalty on net sales of oliceridine in China.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.